BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

774 related articles for article (PubMed ID: 25667205)

  • 61. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
    van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
    Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J
    Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Treatment with tumor necrosis factor inhibitors in axial spondyloarthritis: comparison between private rheumatology practices and academic centers in a large observational cohort.
    Ciurea A; Weber U; Stekhoven D; Scherer A; Tamborrini G; Bernhard J; Toniolo M; Villiger PM; Zufferey P; Kissling RO; Michel BA; Exer P;
    J Rheumatol; 2015 Jan; 42(1):101-5. PubMed ID: 25362654
    [TBL] [Abstract][Full Text] [Related]  

  • 64. An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis.
    Paccou J; Flipo RM
    Drug Des Devel Ther; 2016; 10():2255-62. PubMed ID: 27468228
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Relationship between disease activity status or clinical response and patient-reported outcomes in patients with non-radiographic axial spondyloarthritis: 104-week results from the randomized controlled EMBARK study.
    Dougados M; van der Heijde D; Tsai WC; Saaibi D; Marshall L; Jones H; Pedersen R; Vlahos B; Tarallo M
    Health Qual Life Outcomes; 2020 Jan; 18(1):4. PubMed ID: 31900174
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients.
    van den Brandt S; Zbinden A; Baeten D; Villiger PM; Østensen M; Förger F
    Arthritis Res Ther; 2017 Mar; 19(1):64. PubMed ID: 28320445
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis.
    Tuğsal HY; Artin GK; Can G; Çapar S; Zengin B; Akar S; Dalkiliç HE; Şenel AS; Koca SS; Göker B; Yazici A; İnanç GN; Ellidokuz H; Akkoç N; Önen F
    Turk J Med Sci; 2023 Aug; 53(4):970-978. PubMed ID: 38031953
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy.
    Türk SM; Öztürk Z; Karataş D; Erkorkmaz Ü; Gönüllü E
    Turk J Med Sci; 2022 Apr; 52(2):522-523. PubMed ID: 36161620
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis.
    Dougados M; Wood E; Gossec L; Dubanchet A; Logeart I; van der Heijde D
    J Rheumatol; 2015 Dec; 42(12):2361-8. PubMed ID: 26568588
    [TBL] [Abstract][Full Text] [Related]  

  • 70. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
    Rudwaleit M; Schwarzlose S; Hilgert ES; Listing J; Braun J; Sieper J
    Ann Rheum Dis; 2008 Sep; 67(9):1276-81. PubMed ID: 18006539
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up.
    Kneepkens EL; Krieckaert CL; van der Kleij D; Nurmohamed MT; van der Horst-Bruinsma IE; Rispens T; Wolbink GJ
    Ann Rheum Dis; 2015 Oct; 74(10):1825-9. PubMed ID: 24812290
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity within and outside the home in patients with axial spondyloarthritis, including nonradiographic axial spondyloarthritis and ankylosing spondylitis.
    Osterhaus JT; Purcaru O
    Arthritis Res Ther; 2014 Aug; 16(4):R164. PubMed ID: 25099160
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.
    Levitova A; Hulejova H; Spiritovic M; Pavelka K; Senolt L; Husakova M
    Arthritis Res Ther; 2016 Nov; 18(1):275. PubMed ID: 27887637
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.
    Poddubnyy D; Fedorova A; Listing J; Haibel H; Baraliakos X; Braun J; Sieper J
    J Rheumatol; 2016 Dec; 43(12):2142-2148. PubMed ID: 27803139
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondyltis from a Single Rheumatology Hospital in Morocco.
    Akasbi N; Nihad S; Sofia Z; Khadija EK; Taoufik H
    Curr Rheumatol Rev; 2020; 16(3):240-244. PubMed ID: 30806321
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
    Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
    Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Spectral domain-optical coherence tomographic findings in patients with ankylosing spondylitis under anti-tumor necrosis factor-alpha therapy.
    Ilhan N; Ustun N; Tuzcu EA; Coskun M; Yagiz AE; Ilhan O; Parlakfikirer N
    Cutan Ocul Toxicol; 2015; 34(3):222-6. PubMed ID: 25363064
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three-Year Followup and Predictors.
    van Weely SF; Kneepkens EL; Nurmohamed MT; Dekker J; van der Horst-Bruinsma IE
    Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1522-9. PubMed ID: 26881893
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
    Malaviya AN; Kalyani A; Rawat R; Gogia SB
    Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial.
    Song IH; Weiß A; Hermann KG; Haibel H; Althoff CE; Poddubnyy D; Listing J; Lange E; Freundlich B; Rudwaleit M; Sieper J
    Ann Rheum Dis; 2013 Jun; 72(6):823-5. PubMed ID: 23172749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.